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Department of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical University
<Background> Excessive oxidants play roles in the pathogenesis of glomerular injury. Several studies have 
demonstrated protective effects of edaravone, a free radical scavenger, against renal injury. To clarify the protective 
effects of edaravone, we investigated changes in chemical markers of lipid peroxidation and renal histology in rats 
with chronic puromycin aminonucleoside (PAN) nephrosis (C-PAN). 
<Methods> C-PAN was induced by intraperitoneal injections of PAN (130 mg/kg on day 1 and 60 mg/kg on day 
14). Rats administered normal saline served as controls (n＝5). C-PAN rats were divided into two groups (each 
group: n＝4). In one group (C-PAN＋Eda), rats received 3.0 mg/kg/day of edaravone for five weeks. Blood and 
urinary samples were collected every week. Animals were sacrificed at the end of experiment for histological 
analysis. 
<Results> In C-PAN＋Eda rats, urinary excretion of albumin and 8-isoPGF2α were significantly decreased 
compared with that in C-PAN rats (p＜0.01), whereas levels of urinary thiobarbituric acid-reactive substances 
(TBARS) did not differ between the two groups. On histological examination, the scores for glomerular injury and 
area positive for 4-HNE were significantly lower in C-PAN＋Eda than in C-PAN rats (p＜0.05, p＜0.01, respectively). 
Infiltration of macrophages was also suppressed in C-PAN＋Eda rats.
<Conclusion> Edaravone treatment of C-PAN was able to decrease albuminuria and to ameliorate glomerular 
injury. Levels of several markers related to oxidative stress and lipid peroxidation were reduced after treatment, 
accompanied by reduction of macrophage infiltration and decrease in apoptotic cells in the glomeruli. These 
findings indicate that edaravone has protective effects against the glomerular injury observed in C-PAN nephrosis.
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INTRODUCTION
Recent studies have indicated that reactive oxygen 
species (ROS) and other oxidants play roles in the 
pathogenesis of glomerular injury. Single intraperitoneal 
administration of puromycin aminonucleoside (PAN) 
in rats can induce nephrotic syndrome, characterized 
by  heavy  prote inur ia ,  hypoalbuminemia ,  and 
hypercholesterolemia. This is a well-established animal 
model of human minimal change nephritic syndrome 
(MCNS). On the other hand, the pathologic lesions 
of focal segmental glomerulosclerosis (FSGS) have 
been obser ved in chronic PAN nephrosis (C-PAN) 
induced by repeated intraperitoneal PAN injections in 
rats 1). In chronic PAN nephrosis, several mechanisms 
related to oxidative stress may contribute to podocyte 
injury. It has also been proposed that hyperlipidemia 
may cause renal injury in this model due to the lipid 
peroxidation induced by ROS. Since ROS are highly 
reactive products of oxygen radicals, they can damage 
cellular components including lipids, DNA, and 
proteins. Thakur et al. reported 2) that treatment of PAN 
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nephrosis with hydroxyl radical scavengers resulted in 
reduction of proteinuria.
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, 
MCI-186), a synthetic scavenger of free radicals, 
is an agent newly developed in Japan. It is a potent 
scavenger of hydroxyl radicals, which play a role in lipid 
peroxidation3).  It has been reported to induce acute 
renal disorders in Japan. Post-marketing surveillance 
of edaravone has reported serious adverse reactions, 
including renal and hepatic disorders. Renal disorders 
were the most frequently reported serious/important 
adverse reactions, and this led to determination of 
their causation by edaravone and examination of their 
severity and recovery of renal function. However, a few 
animal and human studies on the efficacy of edaravone 
against chronic glomerular injury have been reported. 
However, these studies repor ted only chemical 
and urinary changes. The crucial issue is whether 
edaravone can cause renal disorder or not. The purpose 
of the present study was therefore to clarify whether 
edaravone has protective ef fects against proteinuria 
and, especially, the renal histological lesions observed 
in a model of C-PAN nephrosis.
Materials and methods
1. Animal experiments
This study was per formed in accordance with a 
protocol established by the animal committee of our 
university. Wistar rats (five-week-old, male) were 
purchased from CLEA Japan Inc. and housed in a 
stable environment in our animal laboratory for 5 days. 
All animals were allowed free access to tap water and 
standard rat chow (CLEA Rodent Diet CE-2, CLEA 
Japan, Inc). 
Experimental schedules were as shown in Figure 1. 
Nephrotic syndrome was induced by intraperitoneal 
injections of PAN (130 mg/kg on day 1 and 60 mg/kg 
on day 14). After the first injection of PAN, the rats were 
divided into two groups. In one group. (C-PAN＋Eda 
rats: n＝4), the rats had an infusion pump implanted 
(2004 ALZET Osmotic Pumps, Cuper tino,  CA) 
subcutaneously, and were continuously administered 
edaravone (Tanabe Mitsubishi Pharma Corporation, 
Japan, 3.0 mg/kg/day). This dose was three times that 
used clinically in humans (1 mg/kg) and suf ficient 
for scavenging of hydroxyl radicals (company data). 
In the other group (C-PAN rats: n＝4), the rats were 
administered normal saline using the same type of 
infusion pump. Rats administered normal saline (0.9％ 
w/v) according to the same schedule as for the C-PAN 
group, and served as control (Controls: n＝5).
Blood and urinary samples were collected from all 
the rats once a week from Week 2 to Week 5. The 24-h 
urinary samples were collected by placing the rats in 
individual metabolic cages. Body weight (BW) and 
renal function were estimated once a week throughout 
the study. All rats were euthanized at the end of the 
experimental period (day 35) and their kidneys were 
Fig. 1. The experimental protocol is shown. C-PAN: chronic puromycin aminonucleoside nephrosis without treatment; C-PAN
＋Eda: chronic puromycin aminonucleoside nephrosis with edaravone treatment (3 mg/kg); control: normal saline injection 
instead of PAN and no treatment.
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removed for histological analysis.
2. Chemical analyses
The methods used to measure serum and urine levels 
of biochemical markers were as follows. Low-density 
lipoprotein (LDL), creatinine (Cr), and urea nitrogen 
(UN) were measured using enzymatic methods; 
albumin (Alb) by the BCG method; urinary albumin by 
nephelometry; thiobarbituric acid-reactive substances 
(TBARS) using hemoglobin-methylene blue4); and 
8-epimer of prostaglandin F2alpha (8-isoPGF2α) by 
ultraviolet absorption spectrophotometry5). Urinary 
albumin excretion (UAE), TBARS, and 8-isoPGF2α 
were corrected by the urine concentration of creatinine 
(mg/dL). All biochemical data were obtained from day 
14 to the end of the experiment (chronic phase). 
3. Histological examination
A semi quantitative score (glomerular injury score: 
GIS) was used to assess the degree of glomerular 
injur y according to the method of Raij et al6). The 
degree of glomerular injury in 50 glomeruli was graded 
using a scale of 0 to 4, based on percentage glomerular 
involvement; score 0: normal, score 1: lesions in up to 
25％ of glomeruli, score 2: lesions in 25-50％, score 3: 
lesions in 50-75％, and score 4: lesions in 75-100％ of 
glomeruli. GIS was then calculated by dividing the total 
score by the total number of glomeruli evaluated. All 
tissues were stained with PAS or PAM.　　　
4. Immunohistochemistry
After antigen retrieval, the slides were incubated 
with 3％ H2O2 at room temperature and then with 
blocking solution (DAKO Protein Block Serum Free, 
Dako Cytomation Inc., Carpinteria, CA); subsequently, 
primary antibodies were used and Dako Cytomation 
EnVision ＋ System-HRP Labelled Polymer (Dako 
Nor thAmerica Inc., Carpinteria, CA) was applied. 
After washing the sections with PBS, they were 
reacted with the horseradish peroxidase substrate 3, 3 
diaminobenzidine (DAB, DAKO JAPAN). Hematoxylin 
was used for counterstaining of nuclei. 
The primary antibodies used in this study were as 
follows: mouse anti-4-hydroxy-2-nonenal (4-HNE) 
antibody (NOF, Tokyo) was used for detection of 
a major lipid peroxidation product, and mouse anti 
ED-1(rat CD68) antibody (MCA341R, AbD SeroTec, 
Oxford, OX5 1GE, UK) was used to detect infiltrating 
macrophages.   
In each slide, 50 randomly selected glomeruli were 
examined, and the area that stained positive for 4-HNE 
was measured using Image J Ver. 1.39 (NIH, USA). 
Numbers of infiltrating macrophages per glomerulus, 
observed as ED-1-positive cells, were counted under 
high-power view (×400). Data are presented as mean 
4-HNE positive area/50 glomeruli and number of ED-1-
positive cells/50 glomeruli.
5. Detection of apoptotic cells
For the detection of DNA fragmentation by terminal 
deoxynucleotidyl transferase-mediated dUTP nick-
end-labeling (TUNEL) assay, sections from paraffin-
embedded kidney tissue were stained using an AP in 
situ cell death detection kit (Roche, Basel Switzerland). 
After deparaf finization and dehydration, apoptotic 
cells were evaluated by TUNEL assay according to the 
manufacturer’s instructions. In brief, the sections were 
incubated in proteinase K working solution (20 μg/mL 
in 10 mmol/L Tris/HCl, pH 7.4〜8.0), and then overlaid 
with 50 μL TUNEL reaction mixture and incubated for 
60 min at 37℃. Thereafter, the sections were overlaid 
with 50 μL converter-peroxidase (POD) with 100 μL 
diaminobenzidine substrate followed by counterstaining 
with hematoxylin and eosin. The percentage of TUNEL-
positive cells was determined in 50 glomeruli per 
animal.   
6. Statistical Analysis
Values are presented as the mean±standard error 
(SE). The paired t-test was used when two groups were 
compared. Simultaneous comparisons involving more 
than two groups were performed by analysis of variance 
(ANOVA) with the Tukey-Kramer test. Findings of 
p＜0.05 were considered significant.
Results
1. Renal Function
In controls, serum levels of UN and creatinine 
remained unchanged throughout the experiment. On 
day 21, serum UN and creatinine concentrations were 
significantly increased in C-PAN and C-PAN＋Eda 
rats compared with controls. However, there were no 
significant differences between the former two groups 
in these parameters, as shown in Tables A and B 
(C-PAN, C-PAN＋Eda, vs. control: UN 72.4 mg/dL and 
75.2 mg/dL vs. 21.9 mg/dL, p＜0.05; Cr 0.49 mg/dL 
and 0.56 mg/dL vs. 0.28 mg/dL, p＜0.05).  
2. Serum lipid profiles
Serum levels of LDL increased and peaked on day 
28 (Table C) in C-PAN and C-PAN ＋ Eda rats, and 
were significantly dif ferent from those in controls 
(C-PAN, C-PAN＋Eda, vs. control: 176.0 mg/dL and 
184.8 mg/dL vs. 8.0 mg/dL, p＜0.05). No significant 
dif ference in this parameter was observed between 
C-PAN and C-PAN＋Eda rats at any time point.   
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3. Excretion of albuminuria and urinary lipid 
peroxidation marker 
The changes in UAE, TBARS, and 8-isoPGF2α are 
shown in Figure 2. In both C-PAN and C-PAN ＋
Eda rats, UAE increased and peaked on day 21, with 
no significant dif ferences between the two groups 
(63.0±4.7 and 56.6±2.7 mg/Cr, respectively; N.S.). 
The dif ference between C-PAN and C-PAN ＋ Eda 
rats reached statistical significance at the end of the 
experiment (46.4±5.3 vs. 37.1±4.5 mg/g・Cr; p＜0.05). 
Urinary TBARS also reached their maximum level in 
C-PAN and C-PAN＋Eda rats on day 21 (0.46±0.22 vs. 
0.35±0.05 μmol/g・Cr, respectively; p＜0.05). On the 
other hand, urinary 8-isoPGF2α reached maximum 
level on day 28 in C-PAN and C-PAN＋Eda rats, while 
in C-PAN＋Eda rats it was significantly lower than in 
C-PAN rats (C-PAN vs. C-PAN＋Eda: 83.7±12.4 vs. 51.3
±19.8 mg/g・Cr; p＜0.05). The difference persisted 
until the end of the study period (48.1±8.1 vs. 28.9±2.3 
mg/g・Cr, respectively; p＜0.05). The level of urinary 
8-isoPGF2α in the C-PAN＋Eda rats on day 35 was 
similar to that of controls (29.9±3.9 mg/g・Cr).
4. Renal Histology
1) Light-microscopic findings: Glomerular injury 
score
Light-microscopic examination revealed several 
histological abnormalities, including segmental 
expansion of the mesangial matrix, obliteration of 
glomerular tufts, adhesion of tufts to Bowman’s capsule, 
and regions of capillary dilatation containing foamy 
cells in the glomeruli of C-PAN rats. Similar findings 
were observed in C-PAN ＋ Eda rats, but they were 
less frequent and milder (Figure 3-B, C, D). There 
were no signs of global sclerosis. Moreover, GIS was 
significantly higher in C-PAN than in C-PAN＋Eda rats
（mean GIS: 1.44±0.09 vs. 0.84±0.15, p＜0.05)(Figure 
3-E).
2) Detection of major lipid peroxidation products 
and oxidative stress
HNE was localized in the mesangial area and tubular 
epithelial cells (Fig. 4-B, C, D). Quantitative findings 
for staining are shown in Figure 4-E. The mean HNE-
positive mesangial area was significantly higher in 
C-PAN rats than in controls (11.16±2.84 vs. 2.62±0.22 
％, p＜0.01). In C-PAN＋Eda rats, immunoreactivity 
to HNE was significantly decreased and HNE-positive 
mesangial area smaller than in the C-PAN (4.17±
0.89％) 
3) Macrophage infiltration
As shown in Figure 5, ED-1-positive cells were 
detected in the glomeruli of C-PAN and C-PAN＋Eda 
rats. Results of semiquantitative determination of the 
number of ED-1-positive cells per glomerulus are shown 
in Figure 5-E. The number of ED-1-positive cells was 
higher in C-PAN rats than in controls but lower than 
that in C-PAN＋Eda rats (4.56±0.23 in C-PAN rats, 1.17
±0.07 in controls, 3.47±0.45 in C-PAN＋Eda rats, p＜
0.05 ). 
Table Changes in concentrations of BUN (A), serum creatinine (B), and serum LDL level (C) during the experiment in C-PAN 
rats, C-PAN＋Eda rats, and negative control. Values are the mean ± SE. (♯p＜0.05 vs. controls, ※p＜0.05 vs. C-PAN rats)
Experimental Days 14 21 28 35
C-PAN 30.7±11.8 72.4±37.6※ 28.8±7.25 20.9±6.27
C-PAN＋Eda 27.5±16.9 75.2±2.1※ 25.8±4.3 17.4±3.4
Negative Control 21.4±4.3 21.9±3.5 21.4±3.3 18.8±3.9
A.  Serum BUN Level
B.  Serum Creatinine Level
Experimental Days 14 21 28 35
C-PAN 0.27±0.11 0.45±0.17※ 0.34±0.10※ 0.23±0.05
C-PAN＋Eda 0.31±0.06 0.56±0.06※ 0.40±0.02※ 0.32±0.06
Negative Control 0.28±0.05 0.28±0.03 0.28±0.02 0.28±0.03
C.  Serum LDL Level
Experimental Days 14 21 28 35
C-PAN 46.6±8.6※ 125.8±26.7※ 176.6±54.0※ 68.3±16.5※
C-PAN＋Eda 70.2±12.8※＃ 134.8±8.5※ 184.8±85.4※ 65.8±22.3※
Negative Control 10.8±1.8　 9.8±1.6 8.0±4.7　 7.6±1.3　
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4) TUNEL-positive cells
The number of TUNEL-positive cells was significantly 
higher in C-PAN rats than in controls but lower than in 
C-PAN＋Eda rats (mean cell count: 10.88±0.34 vs. 9.17
±0.27, p＜0.05) (Fig. 6-B, C, D). However, there were 
still a substantial number of apoptotic cells in C-PAN＋
Eda rats compared with the controls (mean cell count: 
6.77±0.27) (Fig. 6-E).
Discussion
A single injection of PAN can induce marked 
proteinuria without glomerular morphological change 
in rats. On the other hand, repeated injection of PAN 
can induce massive proteinuria associated with FSGS. 
Previous studies suggested that lipid peroxidation was 
the principal cause of PAN-induced nephrotoxicity6, 7)．
In this study, we assessed renal lipid peroxidation 
using two parameters, the urinar y concentrations 
of TBARS and 8-iso-PGF2. Recently, 8-iso-PGF2 
has  come to  be considered the most  re l iable 
biochemical marker of lipid peroxidation. We found 
that urinar y concentrations of TBARS and 8-iso-
PGF2α increased after PAN injection compared with 
controls. However, dif ferent profiles of TBARS and 
8-iso-PGF2α were observed after administration of 
edaravone, a potent inhibitor of lipid peroxidation8,9). 
The urinary concentration of TBARS was significantly 
increased on days 14 to 21 in C-PAN rats. The urinary 
Fig. 2. Changes in concentrations of urinary 
albumin (A), TBARS (B), and 8-isoPGF2α (C) 
during the experiment in controls ( ▲ ), C-PAN 
rats ( ■ ), and C-PAN＋Eda rats ( ● ). 
Values are the mean±SE. (♯p＜0.05 vs. 
controls, ※ p＜0.05 vs. C-PAN rats)
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concentration of 8-isoPGF2α on day 28 in C-PAN rats was 
significantly increased, whereas no increase in urinary 
8-isoPGF2α was observed in C-PAN＋Eda rats. From 
these results we suggest that after PAN treatment, 
increasing oxidative stress levels induced fur ther 
increase in urinary TBARS, and phosphatide which 
enriches existing in LDL surface were oxidized and it 
induced further increase in urinary 8-isoPGF2α levels. 
In this study, edaravone treatment inhibited oxidation 
and resulted significant suppression of urinary TBARS 
and 8-isoPGF2α levels. These findings indicated that 
edaravone could ameliorate urinary protein excretion 
in association with reduction of lipid oxidation. Similar 
protective effects of edaravone against several types of 
renal injury were reported by Matsumura et al10). and 
Someya et al11).
Fig. 3. Representative microscopic findings for glomerular 
lesions observed in PAM-stained specimens. 
A: control (×400), B: C-PAN rat (×400), C: C-PAN rat (×
200) and D: C-PAN＋Eda rat (×400). The glomerular injury 
scores obtained by semiquantitative analysis are shown in 
panel E. Values are the mean±SE. (♯p＜0.05 vs. controls, 
※ p＜0.05 vs. C-PAN rats)
Fig. 4. Immunohistological detection of 4-HNE in a 
control, C-PAN rat, and C-PAN＋Eda rat.  Representative 
photomicrographs are shown in panels A~D. A: control 
(×400), B: C-PAN rat (×400), C: C-PAN rat (×200) and D: 
C-PAN＋Eda rat (×400). Percent areas positively stained for 
4-HNE were measured by an image analyzer and are shown 
in panel E. Values are the mean±SE. (♯p＜0.05 vs. controls, 
※ p＜0.05 vs. C-PAN rats)
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To investigate the ef fects of edaravone on renal 
tissue injury, histological and immunohistochemical 
analyses were performed. The number of glomerular 
macrophages, as determined by ED-1 positivity, was 
significantly increased in C-PAN rats, as previously 
repor ted by Diamond et al12). Native LDL may be 
converted by various mechanisms to oxidized LDL 
(Ox-LDL), which has a specific ligand for the scavenger 
receptor on macrophages 13). Oxidized LDL has been 
shown to be taken up by a “scavenger” receptor, 
distinct from the receptor responsible for the uptake 
of native LDL. Uptake of Ox-LDL by macrophages 
may further stimulate these immune ef fectors cells 
to produce growth factors, cytokines, and other 
mediators 14). Infiltration of stimulated macrophages 
into the glomeruli may stimulate the proliferation of 
Fig. 5. Macrophages were detected by immunohistochemical 
staining as ED-1-positive cells. A: control (×400), B: C-PAN 
rat (×400), C: C-PAN rat (×200) and D: C-PAN＋Eda 
rat (×400). Mean numbers of macrophages are given in panel 
E. Values are the mean±SE. ( ♯ p＜0.05 vs. controls, ※ p＜
0.05 vs. C-PAN rats)
Fig. 6. Immunohistochemical detection of apoptotic cells 
using TUNEL assay. A: control (×400), B: C-PAN rat (×400), 
C: C-PAN rat (×200) and D: C-PAN＋Eda rat (×400).Results 
of quantitative analysis of apoptotic cells are shown in panel E. 
Values are the mean±SE. (♯p＜0.05 vs. controls, ※ p＜0.05 
vs. C-PAN rats) 
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mesangial cells and extracellular matrix synthesis. 
During progression from the acute to the chronic 
phase of renal failure, the infiltrating cells change from 
eosinophils to monocytes/macrophages (ED-1 positive 
cells), or lymphocytes. This change is stimulated by 
monocyte chemoattractant protein-1 (MCP-1) produced 
by mesangial cells. MCP-1 induces worsening of 
glomerular lesions, leading to sclerosis and fibrosis 
in particular. During advanced albuminuria and renal 
dysfunction, ED-1-positive cells further increase with 
worsening of disease15). In the present study, treatment 
with edaravone resulted in significant suppression 
of macrophage infiltration into the glomeruli. Magi 
et al. repor ted that Ox-LDL was usually identified 
in the glomeruli of patients with FSGS, and that a 
decrease in the number of ED-1-positive cells resulted 
in improvement of FSGS16). Macrophages play key 
roles in the early stages of atherosclerosis and in 
the establishment of atherosclerotic lesions that 
contain abundant Ox-LDL17). A similar mechanism 
may contribute to the development of FSGS. Lipid 
peroxidation products, detected using antibody to HNE, 
were located in the mesangial area. The area positively 
stained for HNE was significantly reduced in C-PAN
＋Eda rats compared with C-PAN rats. Decreased 
lipid peroxidation may also reduce proteinuria and 
ameliorate histological changes. In the present study, 
the number of apoptotic cells in the glomeruli was 
significantly increased in chronic PAN rats, and was 
significantly reduced by edaravone treatment. Satoh 
et al. also reported that the number of apoptotic cells 
was significantly reduced by edaravone treatment in 
an experimental model of acute renal injury induced 
by cisplatin in rats18). In their study, although 1 mg/kg 
of edaravone did not reduce the number of TUNEL-
positive cells, 5 mg/kg of edaravone significantly 
reduced their number. In the present study, 3 mg/kg 
of edaravone was used, and this dose appeared to 
be ef fective. Similarly, Iguchi et al19).  repor ted 
that administration of edaravone reduced injur y 
of mitochondria and DNA and renal epithelial cell 
apoptosis in an animal model of cisplatin-induced acute 
renal injury. It thus appears that the effects of edaravone 
may be dose-dependent and that its mode of action may 
involve not only the inhibition of lipid peroxidation but 
also direct protection of cells. Our findings suggest that 
edaravone scavenges ROS and free radicals generated 
systemically, suppresses the change from LDL to 
Ox-LDL . 
In chronic PAN nephrosis, several mechanisms 
related to oxidative stress may contribute to podocyte 
injury. In the present study, severe albuminuria was also 
markedly decreased after treatment with edaravone. 
In addition, treatment with edaravone reduced 
urinary markers related to renal lipid peroxidation 
and improved several morphological changes. These 
findings indicate that renal dysfunction, as defined by 
increase in blood urea nitrogen, creatinine, and LDL, 
did not improve. However, it has not yet been reported 
whether edaravone improves biochemical parameters in 
PAN rats, and edaravone alone cannot rapidly improve 
renal function. Since proteinuria improved without 
changes in serum creatinine or urea nitrogen, this 
proteinuria improvement must have resulted from the 
radical scavenger activity of edaravone. 
Edaravone has been reported to provoke acute renal 
disorder in Japan. However, we found no significant 
differences in renal function between positive control 
rats and edaravone-treated rats. This is important 
in determining whether edaravone can cause renal 
disorder. 
The results of previous studies and our own show that 
edaravone has no effect on renal deficiency at the dose 
employed in this study. In addition, there is no report 
showing improvement of renal function by edaravone 
compared to the C-PAN model with edaravone at the 
dose of 3 mg/kg. In this study, it should be emphasized 
that whether edaravone treatment caused renal 
dysfunction or not. Compared with C-PAN, there 
were no dif ference about serum UN and creatinine 
concentration levels in the C-PAN＋Eda group. From 
this result, we suggested that edaravone did not cause 
further renal function aggravation in the C-PAN group. 
Moreover, concerning the rise in creatinine, in a human 
clinical study performed from phase Ⅰ to phase Ⅲ 
among 549 totals, there were no report to rise in serum 
creatinine. Hishida et al. repor ted a case of renal 
dysfunction caused by edaravone 20,21)  and no significant 
differences were observed in serum creatinine or urea 
nitrogen between control rats and edaravone-treated 
rats using edaravone at a daily dose of 30 mg/kg or 10 
mg/kg i.v for 5 weeks22,23). Since aggravation of renal 
function was noted under conditions of infection, it 
appeared that the likelihood of renal dysfunction being 
caused by edaravone in our C-PAN rats was extremely 
low.
Our findings suggest that the protective ef fects 
of  edaravone are probably exer ted via several 
mechanisms. Additional studies are needed to clarify 
the mechanisms by which edaravone exerts protective 
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effects against glomerular injury.
Conclusion
The progression of renal injury observed in chronic 
PAN nephrosis may be related to the activation of lipid 
peroxidation and infiltration of macrophages into the 
glomeruli. In this model, treatment with edaravone 
resulted in a decrease in albuminuria and amelioration 
o f  g lomer ular  in jur y.  His to logica l  eva luat ion 
demonstrated suppression of macrophage infiltration 
into the glomeruli and reduction of products of lipid 
peroxidation after treatment with edaravone. Over a 
short period of examination, antioxidant treatment thus 
reduced proteinuria and oxidative tissue injury. Longer 
observation is needed to more clearly test the effects of 
antioxidant treatment. 
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0 Tokushi Nakajima, et al
慢性 puromycin aminonucleoside (PAN) nephrosisをもちいたエダラボン（ラジカット®）による糸球体障害への
効果の検討
中島　徳志，叶澤　孝一，御手洗　哲也
≪背景≫種々の病態により生じる酸化ストレスにより腎糸球体は組織学的な障害を受ける．Free radical 
scavengerであるエダラボンによる腎障害への保護効果はいくつか報告されている．この保護作用の機序を解明
するため，我々は慢性 puromycine aminonucleoside (PAN) nephrosisモデルを用いて脂質過酸化のマーカーおよ
び腎組織学的検討を行った．
≪方法≫慢性PANモデルは，PANを腹腔内投与し作成した（第1病日に130 mg/kg，腹腔内投与，第14病日に 60 
mg/kg, 腹腔内投与）．ポジティブコントロール群(慢性PAN）(n＝4)，エダラボン投与群（慢性PAN＋Eda：Eda 3.0 
mg/kg/day）（n＝4）の2群にグループ分けした．また，生理食塩水を腹腔内投与したwistarラット5匹をネガティ
ブコントロール群とした．血液・尿を毎週採取し，実験終了日に麻酔下にラットより腎組織を採取した．
≪結果≫慢性PAN＋Eda群では慢性PAN群に比べ，尿中アルブミン量および8-isoprostane排泄量の有意な低下を
認めた(p＜0.01)．TBARSは，2群間で有意な差を認めなかった．組織学的検討では，慢性PAN＋Eda群がC-PAN
群に比べ，糸球体障害度，4-hydroxy-2-nonenal （4-HNE）陽性面積(p＜0.01)，ED-1陽性細胞浸潤(p＜0.05)，アポ
トーシス細胞数の有意な減少(p＜0.05)を認めた．
≪結論≫エダラボンのC-PAN群に対する投与により，尿中アルブミンを減少させ糸球体障害を改善することが
できた．慢性PANラットにおいて酸化ストレスおよび脂質過酸化に関連するマーカーは治療により減少し，マ
クロファージ浸潤および糸球体でのアポトーシス細胞の減少に相関していた．これら結果より，抗過酸化治療は
C-PANにおいて糸球体障害軽減作用を有する可能性が示唆された． 
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